{"schema_version":"secwatch.filing_event.v1","accession":"0000719135-22-000030","form_type":"8-K","ticker":"APYX","cik":"0000719135","company_name":"Apyx Medical Corp","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.461960+00:00","generated_at":"2026-06-25T19:38:47.272633+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Apyx Medical Q1 revenue up 45% to $12.5M, net loss widens, guidance narrowed","bullets":["Revenue $12.5M (+45% YoY); Advanced Energy $10.8M (+41%), OEM $1.7M (+72%).","Net loss attributable to stockholders $5.9M ($0.17/share) vs $4.9M ($0.14) prior year.","Adjusted EBITDA loss $4.0M vs $3.4M; operating expenses rose 33% to $14.1M.","FY2022 revenue guidance narrowed to $52.5-59.0M (prior $50-63M); Advanced Energy $46-52M (prior $43.5-56M).","FDA Safety Communication in March impacted U.S. new customer adoption; 510(k) submissions for dermal/laxity pending."],"urls":{"canonical":"https://secwatch.observer/filing/0000719135-22-000030","json":"https://secwatch.observer/filing/0000719135-22-000030.json","markdown":"https://secwatch.observer/filing/0000719135-22-000030.md","text":"https://secwatch.observer/filing/0000719135-22-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/719135/000071913522000030/0000719135-22-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/719135/000071913522000030/apyx-20220512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T19:38:47.272633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}